PILOT STUDY OF TOL, TOX & EFF OF BETA INTERFERON IN INCLUSION BODY MY

包涵体肌炎是一种炎性肌病，其确切的发病机制尚不清楚。目前尚无有效的治疗方法。本研究假设免疫介导的肌肉损伤在产生IBM特征的肌肉无力和消瘦中具有主要或次要的重要性。虽然糖皮质激素和其他免疫抑制药物对某些患者的作用不大，但它们通常是有效的。免疫调节剂，特别是干扰素，似乎在许多炎症性疾病中有希望。-干扰素已被批准用于多发性硬化症，多发性硬化症是一种免疫发病机制尚不明确的疾病，皮质类固醇对这种疾病的疗效有限。本研究将调查肌内β -干扰素的耐受性和安全性，并将识别问题和改进各种肌肉测试程序，以优化其作为主要结果测量的有效性。

Inclusion Body Myositis is an inflammatory myopathy whose precise pathogenesis is unknown. It has not effective treatment. This study hypothesizes that immune-mediated muscle damage is of primary or secondary importance in producing the muscle weakness and wasting that characterizes IBM. Although corticosteroids and other immune suppressant medications may be of minor benefit in some patients, they are generally effective. Immunomodulating agents, notably the interferons, appear to hold promise in a number of inflammatory diseases. Beta interferon has been approved for use in multiple sclerosis, a disease with features suggesting a still-undefined immune pathogenesis and for which corticosteroids are of limited benefit. This study will investigate the tolerability and safety of intramuscular Beta interferon and will indentify problems with and refine the various muscle testing procedures to optimize their usefulness as primary outcome measures.